contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


fenja-capital-ii-as-requests-conversion-of-all-outstanding-convertibles-for-a-total-nominal-amount-of-sek-75-million

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Ascelia Pharma

Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) issued on 13 September 2024, convertibles to Fenja Capital II A/S (“Fenja Capital”) with an aggregate nominal amount of SEK 7.5 million....

<div class="mfn-preamble"><p><strong>Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) issued on 13 September 2024, convertibles to Fenja Capital II A/S (“Fenja Capital”) with an aggregate nominal amount of SEK 7.5 million. Fenja Capital has now requested conversion of all outstanding convertibles whereby a total of 2,218,933 new ordinary shares are issued to Fenja Capital at a conversion price of SEK 3.38 per share.</strong></p></div><div class="mfn-body"><p>As a result of the conversion of convertibles, the number of ordinary shares in Ascelia Pharma will increase by 2,218,933, which results in that the total number of outstanding shares in the Company increases from 117,112,647 shares to 119,331,580 shares, whereof 118,244,459 are ordinary shares and 1,087,121 are series C shares. The share capital increases with SEK 2,218,933 from SEK 117,112,647 to SEK 119,331,580. This corresponds to a dilution effect of approximately 1.88 percent of the total number of ordinary shares in the company after the conversion.<br>&nbsp;<br>The cash runway of Ascelia Pharma is now into the second quarter 2026.</p></div><div class="mfn-footer mfn-7f5eadc7c3d3"><p><strong class="mfn-heading-1">About us</strong></p><hr><p>Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit&nbsp;<a rel="noopener" href="http://www.ascelia.com/">http://www.ascelia.com.</a></p></div><div class="mfn-footer mfn-5c7f03d9b448"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Magnus Corfitzen, CEO<br>Email:&nbsp;<a rel="noopener" href="mailto:moc@ascelia.com">moc@ascelia.com</a><br>Tel: +46 735 179 118</p><p>Julie Waras Brogren, Deputy CEO (Finance, Investor Relations &amp; Commercial)<br>Email:&nbsp;<a rel="noopener" href="mailto:jwb@ascelia.com">jwb@ascelia.com</a><br>Tel: +46 735 179 116</p><p><em>This information was submitted for publication, through the agency of the contact persons set out above.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/f77214f7-7cc5-4e75-aa61-4144fc45955d/fenja-capital-ii-a-s-requests-conversion-of-all-outstanding-convertibles-for-a-total-nominal-amount-of-sek-7-5-million.pdf" class="mfn-generated mfn-primary">Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million</a></p></div>

Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million